GW Pharmaceuticals Share Price (GWP)

0.00 0.00 (0.00%) delayed: 1:25AM GMT
Bid price 0.00 Open price 0.00
Ask price 0.00 Prev close 735.00
High price 0.00 Spread 0.00%
Low price 0.00 Volume 0

Register now for FREE live GW Pharmaceuticals share prices, GW Pharmaceuticals stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get GW Pharmaceuticals Level 2 Data, indepth research tools and investor commentary for GW Pharmaceuticals (GWP) and other London Stock Exchange equities.

GW Pharmaceuticals Share Price Chart

Advanced Charts >>

Register now for FREE GW Pharmaceuticals share price charts

GW Pharmaceuticals Share Price Information

Name GW Pharmaceuticals Epic GWP
Sector Pharmaceuticals & Biotechnology ISIN GB0030544687
Activites GW Pharmaceuticals PLC is licensed by the UK Home Office to work with a range of controlled drugs for medical research purposes. The Group's lead programme is the development of a product portfolio of non-smoked prescription medicines derived from cannabis, including Sativex®, to meet patient needs in a wide range of therapeutic indications. The Group has also expanded its research to include the use of other controlled drugs in conjunction with its proprietary secure drug dispensing technology. GW's lead product, Sativex®, was approved by Health Canada in April 2005 for the relief of neuropathic pain in Multiple Sclerosis (MS) and was launched in Canada in June 2005 by Bayer HealthCare who will exclusively market Sativex® in Canada. GW maintains control over all aspects of the product development process - botanical research, cultivation, extraction, formulation into drug delivery technologies, clinical trials and regulatory affairs. With a view to encouraging exploratory research and identifying future product opportunities, GW established in March 2002 a separate division called the Cannabinoid Research Institute or 'CRI'. The CRI aims to link industry and academia in conducting exploratory research which it is hoped will lead to the identification of new indications for cannabis-based medicines and greater understanding of the mechanism of action of cannabinoids. GW has also developed a novel, secure and tamper-proof means of dispensing drugs. The technology is called the Advanced Dispensing System (ADS) and provides high levels of security for dispensing drugs, whilst also enabling clinicians to remotely monitor and, if required, remotely control drug usage in real time. In October 2003, ADS won the AiM Stock Exchange 'Best Technology' Award. Index n/a

GW Pharmaceuticals Key Numbers

Latest Share Price (p) 0.00 Net Gearing (%) -65.71
Market Capitalisation (£m) 2,223.07 Gross Gearing (%) 15.35
Shares in issue (m) 302.46 Debt Ratio 6.38
P/E Ratio -26.83 Debt-to-Equity Ratio 0.38
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.18
Dividend Yield (%) 0.00 Price to book value 5.99
Dividend cover (x) 0.00 ROCE (%) -21.78
Earning per share (p) -27.40 EPS Growth (%) -142.48
52 week high / low 900.00 / 676.00 DPS Growth (%) n/a

GW Pharmaceuticals Director Deals

Dec.Date Type Director Pos No. of Shares
10/11/2016 SELL Tom Lynch NED 2,074
28/10/2016 SELL Dr Geoffrey Guy CH 300,000
26/10/2016 TOUT Dr Geoffrey Guy CH 250,000
25/10/2016 SELL Dr Stephen Wright ED 1,556
25/10/2016 SELL Dr Geoffrey Guy CH 206,100

More GW Pharmaceuticals Director Deals >>

GW Pharmaceuticals Company News

More GW Pharmaceuticals Company News >>

Register now for FREE GW Pharmaceuticals company news

GW Pharmaceuticals Share Price Discussions

more than 1 year ago

GW Pharmaceuticals (GWP)

Hi , Dunno about you but this looks very promising a they are in last approval stages

more than 1 year ago

GWP's cannabis drug to be widely available soon (GWP)

Cannabis MS drug seeks approval September 2006 The Daily Telegraph By Rosie Murray-West, Business Correspondent The first medicinal product based on cannabis was filed for approval in Britain yesterday, and could be widely available in a year's time. Sativex, based on cannabis extract, is...

more than 1 year ago

Greenwich Pharmaceuticals (GWP)

After years of getting governmental marketing approvals it seems that GWP flagship drug Sativex is at last taking off

Register now for FREE GW Pharmaceuticals share price discussions